agenda 2023 02 22 24 508

Final - February 17, 2023
MEETING OF THE ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES (ACIP)
Centers for Disease Control and Prevention
Atlanta, Georgia 30329
February 22-24, 2023
Wednesday, February 22, 2023
8:00 Welcome & Introductions  Dr. Grace Lee (ACIP, Chair)
Dr. Melinda Wharton (ACIP Executive Secretary, CDC)
8:30 Mpox Vaccine
Introduction Epidemiology of mpox during 2022 outbreak in the United States
JYNNEOS vaccine safety
JYNNEOS vaccine effectiveness Mpox vaccine acceptability and uptake from cross-sectional surveys
Interim clinical considerations
EtR: Use of JYNNEOS during mpox outbreaks Dr. Pablo Sanchez (ACIP, WG Chair)
Dr. Sascha Ellington (CDC/NCCDPHP)
Dr. Jonathan Duffy (CDC/NCEZID)
Dr. Anna Chard (CDC/NCIRD) Dr. Kevin P. Delaney (CDC/NCHHSTP)
Dr. Rosalind Carter (CDC/NCIRD)
Dr. Agam Rao (CDC/NCEZID)
11:30 Break
12:30 Respiratory disease surge, Fall 2022, United States Dr. José R. Romero (CDC, Director NCIRD)
1:00 Influenza Vaccine
Introduction U.S. Influenza activity update Preliminary 2022-23 influenza vaccine effectiveness: CDC networks
Preliminary 2022-23 influenza vaccine effectiveness: Wisconsin Dr. Keipp Talbot (ACIP, WG Chair)
Dr. Lisa Grohskopf (CDC/NCIRD) Ms. Samantha Olson, Dr. Nathaniel Lewis, Dr. Mark
Tenforde (CDC/NCIRD)
Dr. Huong McLean, Marshfield Clinic Research Institute
1:50 Break
2:00 Public Comment
2:30 VOTES
Mpox Dr. Agam Rao (CDC/NCEZID)
2:50 Break
3:00 Pneumococcal Vaccines
Introduction
Epidemiology of pneumococcal disease among U.S. children Estimating the impact of higher-valency PCVs on pediatric outpatient ARI
visits and antibiotic use
PCV20 Phase 2/3 study results among children
Preliminary EtR (incl. GRADE) for PCV20 use in U.S. children
Workgroup considerations Dr. Katherine Poehling (ACIP, WG Chair) Mr. Ryan Gierke (CDC/NCIRD) Ms. Laura King (UC Berkeley)
Dr. Wendy Watson (Pfizer)
Dr. Miwako Kobayashi (CDC/NCIRD) Dr. Miwako Kobayashi (CDC/NCIRD)
5:00 Adjourn
Thursday, February 23, 2023
8:00 Welcome & Introductions  Dr. Grace Lee (ACIP, Chair)
Dr. Melinda Wharton (ACIP Executive Secretary, CDC)
8:10 Agency Updates
CDC, CMS, FDA, HRSA, IHS, OIDP, NIH
8:30 Meningococcal Vaccines
Introduction
Epidemiology of meningococcal disease in the United States
Pfizer pentavalent meningococcal vaccine
Workgroup considerations Dr. Kathy Poehling (ACIP, WG Chair) Ms. Amy Rubis (CDC/NCIRD)
Dr. Jason Maguire (Pfizer)
Dr. Sam Crowe (CDC/NCIRD)
9:30 Polio Vaccine
Introduction Dr. Oliver Brooks (ACIP, WG Chair) Dr. Sarah Kidd (CDC/NCIRD)
Recommendations for Adult Polio Vaccination
10:00 Break

 Final - February 17, 2023
10:20 RSV Vaccines - Pediatric/Maternal
Introduction
Cost effectiveness analysis for nirsevimab – CDC model Cost effectiveness analysis for nirsevimab – Comparison to manufacturer
model
Evidence to Recommendations framework for nirsevimab
Clinical considerations for nirsevimab Safety and Efficacy of RSV Bivalent PreF Maternal Vaccine Workgroup considerations Dr. Sarah Long (ACIP, WG Chair) Dr. David Hutton (University of Michigan) Dr. Ismael Ortega Sanchez (CDC/NCIRD)
Dr. Jefferson Jones (CDC/NCIRD)
Dr. Jefferson Jones (CDC/NCIRD) Dr. Iona Munjal (Pfizer) Dr. Katherine Fleming-Dutra (CDC/NCIRD)
12:20 Break
1:20 RSV Vaccines - Adult
Introduction Cost effectiveness of the GSK and Pfizer vaccines (main CDC model)
Comparison of cost effectiveness results of the main CDC model and each
manufacturer model (GSK & Pfizer)
EtR (incl. GRADE) for 2 vaccines (GSK & Pfizer)
Vaccine policy questions (GSK & Pfizer) Dr. Camille Kotton (ACIP, WG Chair) Dr. David Hutton (University of Michigan)
Dr. Ismael Ortega Sanchez (CDC/NCIRD)
Dr. Michael Melgar (CDC/NCIRD)
Dr. Michael Melgar (CDC/NCIRD)
3:05 Break
3:25 Chikungunya Vaccine
Introduction Global epidemiology of chikungunya Chikungunya in U.S. travelers Persistent arthralgia following chikungunya Workgroup considerations Dr. Beth Bell (ACIP, WG Chair)
Dr. Susan Hills (CDC/NCEZID) Ms. Nicole Lindsey (CDC/NCEZID) Ms. Nicole Lindsey (CDC/NCEZID) Ms. Nicole Lindsey (CDC/NCEZID)
4:25 Dengue Vaccines
Introduction Takeda dengue vaccine (TAK-003) safety and efficacy Workgroup considerations Dr. Wilbur Chen (ACIP, WG Chair) Dr. Shibidas Biswal  (Takeda) Dr. Gabriela Paz-Bailey (CDC/NCEZID)
5:10 Varicella
Public health impact of 25 years of varicella vaccination in the United States Dr. Mona Marin (CDC/NCIRD)
5:30 Adjorn
Friday, February 24, 2023
8:00 Welcome & Introductions Dr. Grace Lee (ACIP, Chair)
Dr. Melinda Wharton (ACIP Executive Secretary, CDC)
8:10 COVID-19 Vaccines
Introduction Dr. Matthew Daley (ACIP, WG Chair)
COVID-19 vaccine safety updates: CDC Dr. Tom Shimabukuro (CDC/NCEZID)
COVID-19 vaccine safety updates: FDA Dr. Richard Forshee (FDA)
VaST summary Dr. Keipp Talbot (ACIP, VaST Co-Chair)
WG interpretation and summary Dr. Evelyn Twentyman (CDC/NCIRD)
9:30 Break
9:45 Updates on COVID-19 hospitalizations: COVID-NET Dr. Chris Taylor (CDC/NCIRD)
Updates to COVID-19 vaccine effectiveness in the United States Dr. Amadea Britton (CDC/NCIRD)
Considerations for transitioning to bivalent primary series Dr. Sara Oliver (CDC/NCIRD)
11:30 Break
11:45 Benefit/risk for COVID-19 vaccines Dr. Megan Wallace (CDC/NCIRD)
COVID-19 vaccines: future directions Dr. Sara Oliver (CDC/NCIRD)
1:45 Adjorn

 Final - February 17, 2023
Acronyms
ARI Acute respiratory illness
CDC Centers for Disease Control and Prevention
CMS Centers for Medicare and Medicaid Services
COVID-19 Coronavirus disease 2019
EtR Evidence to Recommendations Framework
FDA Food and Drug Administration
GRADE Grading of Recommendations Assessment, Development and Evaluation
HRSA Health Resources and Services Administration
IHS Indian Health Service
NCHHSTP National Center for HIV, Hepatitis, STD and TB Prevention [of CDC/OID]
NCIRD National Center for Immunization & Respiratory Diseases [of CDC/OID]
NCEZID National Center for Emerging and Zoonotic Diseases [of CDC/OID]
NIAID National Institute of Allergy and Infectious Diseases
OIDP Office of Infectious Disease and HIV/AIDS Policy
PCV20 20-valent pneumococcal conjugate vaccine
SARS-CoV-2 Severe Acute Respiratory Syndrome Coronavirus 2
VaST COVID-19 Vaccine Safety Technical Work Group
WG Work Group
WHO World Health Organization
VE Vaccine Effectiveness

Summary: Final - February 17, 2023  MEETING OF THE ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES (ACIP)  Centers for Disease Control and Prevention  Atlanta, Georgia 30329  February 22-24, 2023  Wednesday, February 22, 2023  8:00 Welcome & Introductions  Dr. Grace Lee (ACIP, Chair)  Dr. Melinda Wharton (ACIP Executive Secretary, CDC)  8:30 Mpox Vaccine  Introduction Epidemiology of mpox during 2022 outbreak in the United States  JYNNEOS vaccine safety  JYNNEOS vaccine effectiveness Mpox vaccine…